Look­ing for an edge in a com­pet­i­tive mar­ket, Ox­ford Nanopore moves in­to mR­NA vac­cine test­ing

Re­searchers at the Uni­ver­si­ty of Queens­land say they’ve de­vel­oped a faster way to put mR­NA vac­cines through qual­i­ty con­trol test­ing, ac­cord­ing to a study pub­lished to­day in Na­ture Com­mu­ni­ca­tions.

Ox­ford Nanopore, the com­pa­ny whose tech­nol­o­gy is in­te­gral to the process, is tout­ing the find­ings as it looks for an edge in the in­creas­ing­ly com­pet­i­tive space of ge­net­ic se­quenc­ing. Com­pa­nies like Ox­ford Nanopore and Il­lu­mi­na read DNA for re­search and di­ag­nos­tic pur­pos­es, but Ox­ford Nanopore sees big po­ten­tial in test­ing mR­NA vac­cines and ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER